Magnesium Sulphate Reduces Cerebral Palsy Risk in Preterm Infants

Understanding Magnesium Sulphate and Preterm Risks

Babies born prematurely before 37 weeks of pregnancy face elevated risks of severe health complications, including mortality and long-term disabilities such as cerebral palsy. According to the systematic review authored by Emily S Shepherd and colleagues, magnesium sulphate is a widely utilized medication around the world for managing various pregnancy complications. In recent years, clinicians have administered the drug to mothers likely to experience spontaneous preterm labor or scheduled for early induction and cesarean birth to help protect fetal brains. The updated review builds on foundational findings established in a 2009 Cochrane evaluation, which first demonstrated the neuroprotective benefits of the therapy. International medical guidelines now recommend the practice for preterm cerebral palsy prevention. The latest update, current to March 17, 2023, incorporated new randomized controlled trials and extended follow-up data to re-examine the therapy’s safety and effectiveness profile.

Clinical Findings on Child Outcomes at Two Years

To determine the safety and efficacy of the intervention, researchers analyzed six randomized controlled trials involving 5,917 women and their 6,759 fetuses or babies. All included studies took place in high-income nations and compared intravenous, intramuscular, or oral administration of magnesium sulphate against a placebo or no treatment. The analysis revealed clear neurological benefits for infants evaluated up to two years of corrected age. Compared with a placebo, administration of magnesium sulphate led to the following outcomes:

• Reduced cases of cerebral palsy, supported by evidence from six studies encompassing 6,107 children, yielding a risk ratio of 0.71 and a number needed to treat for an additional beneficial outcome of 60.
• Decreased rates of the combined outcome of death or cerebral palsy, drawn from six studies with 6,481 children, showing a risk ratio of 0.87 and a number needed to treat of 56.
• Little to no discernible difference in overall mortality up to two years of age, based on six studies involving 6,759 children.
• Little to no difference in major neurodevelopmental disability, evaluated across three studies comprising 4,279 children.

Safety Profile and Treatment Side Effects

While infant benefits are supported by high-certainty evidence, researchers evaluated maternal outcomes to understand treatment tolerability. Data from four studies involving 5,300 women indicated that magnesium sulphate may make little to no difference in serious maternal complications, such as cardiac or respiratory arrest and death. However, the review found that the therapy probably increases the likelihood of women stopping treatment prematurely due to side effects. This conclusion, backed by moderate-certainty evidence from three studies covering 4,736 women, varied across trials due to differing clinical decision-making processes regarding when to discontinue administration.

Evidence Limitations and Future Research Directions

Although authors expressed high confidence in findings related to cerebral palsy reduction up to two years of age, certainty diminished regarding older children. Evidence concerning outcomes at early school age remains limited because studies could not track all participating children and long-term data sets remain small. Consequently, investigators noted that results for school-aged children might shift as further studies mature. Future research initiatives in perinatal neuroprotection will need to examine treatment impacts on individuals during adolescence and adulthood. Investigators also emphasized the necessity of studying how specific subgroups of women at risk of preterm birth respond to varied dosage regimens and administration methods of magnesium sulphate.